BMS-470539 is a synthetic MC1R agonist with potent anti-inflammatory properties; it selectively activates human and murine MC1R (EC50 = 16.8 nM and 11.6 nM, respectively); it dose-dependently inhibits TNF-alpha-induced NF-kB activation in human melanoma cells expressing MC1R; in vivo, it effectively suppresses LPS-induced TNF-alpha production in BALB/c mice (ED50 ≈ 10 μmol/kg, pharmacodynamic half-life ≈ 8 hours); it significantly reduces leukocyte infiltration in a lung inflammation model and attenuates paw swelling in a delayed-type hypersensitivity model, highlighting its efficacy as an anti-inflammatory agent mediated through MC1R activation.